Glucotrack, Inc. · NASDAQ:GCTK
Glucotrack — Investor Presentation (May 2025)
25 slides from Glucotrack's investor presentation, May 2025
Slide 1: Revolutionizing Glucose Monitoring
Revolutionizing Glucose Monitoring A fully implantable system for Continuous Blood Glucose Monitoring May 2025 © Copyright 2025. All rights reserved. Glucotrack.
Slide 2: Important Disclaimers
Important Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Without limitin
Slide 3: Glucotrack: Redefining the future of glucose monitoring
Glucotrack: Redefining the future of glucose monitoring Our mission is to push the boundaries of diabetes management Continuous Blood Glucose Monitor (CBGM) Glucotrack’s fully implantable, long-term system is designed to be less intrusive, more accurate, and dramatically easier to live with than tra
Slide 4: Designed for the market's gaps. Built for the market's growth.
Designed for the market’s gaps. Built for the market’s growth. Differentiated product • Fully implantable CBGM system offering 3 years of continuous monitoring with no wearable • Eliminates key CGM barriers: discomfort, visibility, short sensor life, and daily maintenance • Built on proven cardiovas
Slide 5: An experienced team to deliver the next standard of care
An experienced team to deliver the next standard of care Paul V. Goode, PhD Mark Tapsak, PhD Peter Wulff, MBA Drinda Benjamin, MBA President & CEO Chief Scientific Officer Chief Financial Officer VP, Marketing • Glucose monitoring • Glucose monitoring • Structural heart • Glucose monitoring • Implan
Slide 6: Innovation in glucose monitoring can't wait
Innovation in glucose monitoring can’t wait The diabetes crisis is driving systemic strain 1 in 10 adults have diabetes---that’s a total of 38 million adults (and it’s the 8th-leading cause of death in the United States) 1 Diabetes is the #1 cause of >25% of US healthcare dollars blindness in adults
Slide 7: A sizeable global diabetes market… and CGM is just getting started
A sizeable global diabetes market… and CGM is just getting started Growth by Product Type (2006–2024)1 • CGM (pink) ranks among the fastest-growing categories (and is the fastest-growing device), seeing consistent year-over-year growth – There’s a long runway ahead—especially for innovations that ca
Slide 8: The CGM market is growing rapidly… but ~50% remains untapped
The CGM market is growing rapidly… but ~50% of the market in key segments remains untapped CGM Global Quarterly Revenue ($ millions)1 • $11.6B global CGM market in 20241 (approximately 50% US) – Q4 2025 revenue of $3.2B; +19%YOY; +11% sequential • Since 1999 CGM adoption increased dramatically becom
Slide 9: What's holding CGM back? Barriers to broader adoption
What’s holding CGM back? Barriers to broader adoption Short sensor life limits convenience On-body discomfort drives drop-off CGMs require replacement every 10–15 System can be uncomfortable, fall off prematurely days, adding to user burden and interfere with exercise, sleep, and daily activities La
Slide 10: What patients want (but still are not getting)
What patients want (but still are not getting) Unaddressed patient needs growing in importance Source: dQ&A Q1 2018 Market Research - Base CGM users (N=1,306); dQ&A Q3 2023 Market Research - Base CGM users (N=3,426). 10 © Copyright 2025. All rights reserved. Glucotrack.
Slide 11: The Glucotrack solution: a breakthrough long-term CBGM system
The Glucotrack solution: a breakthrough long-term CBGM system • A first-of-its-kind system that combines the best of glucose monitoring and cardiac monitoring technology in one device • Built from FDA-approved components and familiar techniques to accelerate development and reduce regulatory risk =
Slide 12: Unlocking the full potential of CBGM
Unlocking the full potential of CBGM The CGM market isn’t just underpenetrated—it’s underserved Non-Users With Dissatisfied Satisfied Disconnected/ Known Barriers CGM Users CGM Users Unengaged • Avoid CGMs due to cost, • Struggle with on-body • Already well-served • Not currently tracking discomfort
Slide 13: Market segmentation: CGM non-users (~5M US)
Market segmentation: CGM non-users (~5M US) Non-users with known barriers, disconnected/unengaged Tier Est. share Description Opportunity Ready for CGM or ex-users but Would try a more discreet, Early adopters 20% (~1M) held back by skin irritation, implantable option like Glucotrack stigma, or hass
Slide 14: Market segmentation: Current CGM users (~5M US)
Market segmentation: Current CGM users (~5M US) Dissatisfied CGM users Studies show 25%–35% of users discontinue or are dissatisfied with device burden, adhesive issues, alerts, and supply hassles • Addressable switchers: ~1.5M–1.75M users – Glucotrack value prop aligns perfectly with these burdens
Slide 15: Total opportunity from switchers and non-users
Total opportunity from switchers and non-users Glucotrack addresses both: those left behind and those ready to leave current tech Glucotrack offers broad appeal to the 10M patients in underserved segments 15 © Copyright 2025. All rights reserved. Glucotrack.
Slide 16: Development and regulatory timeline
Development and regulatory timeline OUS study Long-term OUS 6-mo Data study begins Acute study 1 OUS study week 3-mo Data Near-term milestones 2025 further establishing product performance; FDA regulatory process started US Pilot IDE approval US Pilot IDE submission US Pilot study US Pilot begins Pr
Slide 17: Development and regulatory timeline
Development and regulatory timeline OUS study US Pilot OUS study 12-mo data 12-mo data 24-mo data FDA submission (1-year data) Proven clinical and regulatory strategy 2026 2027 2028 for FDA approval and commercialization US pivotal IDE submission US pilot US pilot 6-mo Data 24-mo data US launch US p
Slide 18: Engineered for what patients want (and conventional CGMs still can't deliver)
Engineered for what patients want (and conventional CGMs still can’t deliver) Unsurpassed longevity: Placed once every 3 years in a 20-minute outpatient procedure (vs every 15 days) Wearable-free comfort: Fully implantable design eliminates on-body devices, improving lifestyle fit Implant once. and
Slide 19: First-in-human study results: short-term OUS study
First-in-human study results: short-term OUS study Primary endpoint achieved: No serious adverse events reported Secondary endpoint met: Successful lead insertion & removal • Procedure performed under local anesthesia • Percutaneous lead insertion into subclavian vein using ultrasound & Seldinger te
Slide 20: First-in-human study results cont.
First-in-human study results cont. Device performance • Sensor lead & electronics performed as expected • The prototype system accurately captured and stored sensor data throughout the insertion period, achieving a 99% data capture rate Our first-in-human results confirm the CBGM technology is ready
Slide 21: Poised for impact. Positioned for growth.
Poised for impact. Positioned for growth. Glucotrack is pioneering a fully implantable, long-term CBGM system engineered to overcome the limitations of traditional CGMs Unlock adoption among Benefit from strong market the ~50% of patients not tailwinds in diabetes, digital using CGM today With a pro
Slide 22: APPENDIX
APPENDIX © Copyright 2025. All rights reserved. Glucotrack.
Slide 23: Scientific meeting presentations
Scientific meeting presentations In Vivo Evaluation of Novel Long-Term Intravascular Continuous Blood Glucose Monitor in a Chronic Ovine Model Authors: Paul V Goode, PhD; Michael Talcott, DVM; JP Thrower, PhD; Timothy L Routh, M Eng.; Jose Garcia; Stephen T Tapsak; Samantha Wakil, PhD; Mark A Tapsak
Slide 24: Experienced, Dedicated Board of Directors
Experienced, Dedicated Board of Directors Mr. Malavé brings more than 30 years of leadership in the MedTech industry, primarily in diabetes management. He has extensive expertise in product development, operations, Luis J. Malavé, Chair marketing, strategic partnerships, and FDA regulatory strategy.
Slide 25: Thank You
Thank You 25 © Copyright 2025. All rights reserved. Glucotrack.